Citius Oncology, Inc. Financials
This page shows Citius Oncology, Inc. (CTOR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing is carrying an asset build without reported revenue, while inventory-heavy current assets keep near-term liquidity tight.
In FY2025, financing inflows of$15.2M exceeded the combined cash used in operations and investing, so new capital was doing more than just replenishing cash. Shares outstanding also climbed from 71.6M to 83.5M, which suggests the company’s balance-sheet support was still coming from capital raising while the business remained cash-consuming.
The balance sheet looks stronger on paper than in immediate liquidity: equity was
The cost base kept expanding even without reported revenue, with R&D rising to
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Citius Oncology, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Citius Oncology, Inc. carries a low D/E ratio of 1.25, meaning only $1.25 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 77/100, indicating a strong balance sheet with room for future borrowing.
Citius Oncology, Inc.'s current ratio of 0.56 is below the typical benchmark, resulting in a score of 5/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Citius Oncology, Inc. generates a -55.2% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -45.8% the prior year.
Citius Oncology, Inc. passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Citius Oncology, Inc. generates $0.22 in operating cash flow (-$5.5M OCF vs -$24.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Citius Oncology, Inc. earns $-107.9 in operating income for every $1 of interest expense (-$23.5M vs $218K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Citius Oncology, Inc. reported -$24.8M in net income in fiscal year 2025. This represents a decrease of 17.1% from the prior year.
Citius Oncology, Inc. earned $-0.34 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 9.7% from the prior year.
Cash & Balance Sheet
Citius Oncology, Inc. held $3.9M in cash against $0 in long-term debt as of fiscal year 2025.
Citius Oncology, Inc. had 84M shares outstanding in fiscal year 2025. This represents an increase of 16.7% from the prior year.
Margins & Returns
Citius Oncology, Inc.'s ROE was -55.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 9.3 percentage points from the prior year.
Capital Allocation
Citius Oncology, Inc. invested $6.4M in research and development in fiscal year 2025. This represents an increase of 30.3% from the prior year.
CTOR Income Statement
| Metric | Q3'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7M-57.7% | $3.9M | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | $329K-58.3% | $789K | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $1.3M-57.6% | $3.2M | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $1.1M+6.0% | $1.0M | N/A | $938K-70.1% | $3.1M+148.3% | $1.3M | N/A | $1.1M |
| SG&A Expenses | $23.6M+726.3% | $2.9M | N/A | $1.9M-16.1% | $2.2M-32.5% | $3.3M | N/A | $1.5M |
| Operating Income | -$28.6M-444.8% | -$5.3M | N/A | -$4.9M | N/A | -$6.4M | N/A | -$4.6M |
| Interest Expense | $33K-27.9% | $46K | N/A | $161K | N/A | N/A | N/A | N/A |
| Income Tax | -$231K-187.5% | $264K | N/A | $264K0.0% | $264K0.0% | $264K | N/A | $144K |
| Net Income | -$26.6M-380.8% | -$5.5M | N/A | -$5.4M+30.6% | -$7.7M-16.2% | -$6.7M | N/A | -$4.8M |
| EPS (Diluted) | $-0.27-350.0% | $-0.06 | N/A | $-0.08+27.3% | $-0.11-22.2% | $-0.09 | N/A | $-0.07 |
CTOR Balance Sheet
| Metric | Q3'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $100.7M-8.4% | $110.0M+8.9% | $100.9M+10.1% | $91.7M+0.3% | $91.4M+1.1% | $90.5M+7.2% | $84.4M+71.5% | $49.2M |
| Current Assets | $29.4M-20.8% | $37.1M+34.9% | $27.5M+50.4% | $18.3M+1.5% | $18.0M+5.6% | $17.1M+55.7% | $11.0M+26661.2% | $41K |
| Cash & Equivalents | $2.6M-63.9% | $7.3M+85.9% | $3.9M+3504282.1% | $1120.0% | $1120.0% | $1120.0% | $112-57.1% | $261 |
| Inventory | $22.7M+0.1% | $22.6M+1.6% | $22.3M+29.5% | $17.2M+12.2% | $15.3M+6.7% | $14.4M+73.9% | $8.3M | N/A |
| Accounts Receivable | $1.1M-73.4% | $4.0M | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $65.4M+26.9% | $51.6M-8.1% | $56.1M-5.5% | $59.3M+6.3% | $55.8M+13.4% | $49.2M+28.7% | $38.2M+18.9% | $32.2M |
| Current Liabilities | $58.8M+31.5% | $44.7M-9.7% | $49.5M-6.6% | $53.0M+6.5% | $49.7M+14.6% | $43.4M+32.7% | $32.7M+961.4% | $3.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $35.3M-39.6% | $58.4M+30.2% | $44.9M+38.5% | $32.4M-9.1% | $35.6M-13.7% | $41.3M-10.5% | $46.1M+170.9% | $17.0M |
| Retained Earnings | -$96.2M-38.2% | -$69.6M-8.6% | -$64.0M-8.5% | -$59.0M-10.0% | -$53.7M-16.8% | -$45.9M-17.0% | -$39.3M-1192.0% | -$3.0M |
CTOR Cash Flow Statement
| Metric | Q3'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.8M+47.9% | -$7.4M | N/A | N/A | N/A | N/A | N/A | -$366K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$600K+86.4% | -$4.4M | N/A | N/A | N/A | N/A | N/A | $69K |
| Financing Cash Flow | -$231K-101.5% | $15.1M | N/A | N/A | N/A | N/A | N/A | $264K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CTOR Financial Ratios
| Metric | Q3'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 80.3%+0.3pp | 80.0% | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -1716.2%-1583.0pp | -133.2% | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -1596.0%-1455.7pp | -140.3% | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -75.4%-66.0pp | -9.5% | N/A | -16.6%+5.1pp | -21.7%-5.6pp | -16.1% | N/A | -28.0% |
| Return on Assets | -26.4%-21.4pp | -5.0% | N/A | -5.9%+2.6pp | -8.5%-1.1pp | -7.4% | N/A | -9.7% |
| Current Ratio | 0.50-0.3 | 0.83+0.3 | 0.56+0.2 | 0.35-0.0 | 0.36-0.0 | 0.39+0.1 | 0.34+0.3 | 0.01 |
| Debt-to-Equity | 1.86+1.0 | 0.88-0.4 | 1.25-0.6 | 1.83+0.3 | 1.57+0.4 | 1.19+0.4 | 0.83-1.1 | 1.89 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: The current ratio is below 1.0 (0.56), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
Is Citius Oncology, Inc. profitable?
No, Citius Oncology, Inc. (CTOR) reported a net income of -$24.8M in fiscal year 2025.
What is Citius Oncology, Inc.'s return on equity (ROE)?
Citius Oncology, Inc. (CTOR) has a return on equity of -55.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Citius Oncology, Inc.'s operating cash flow?
Citius Oncology, Inc. (CTOR) generated -$5.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Citius Oncology, Inc.'s total assets?
Citius Oncology, Inc. (CTOR) had $100.9M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Citius Oncology, Inc. spend on research and development?
Citius Oncology, Inc. (CTOR) invested $6.4M in research and development during fiscal year 2025.
What is Citius Oncology, Inc.'s current ratio?
Citius Oncology, Inc. (CTOR) had a current ratio of 0.56 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Citius Oncology, Inc.'s debt-to-equity ratio?
Citius Oncology, Inc. (CTOR) had a debt-to-equity ratio of 1.25 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Citius Oncology, Inc.'s return on assets (ROA)?
Citius Oncology, Inc. (CTOR) had a return on assets of -24.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Citius Oncology, Inc.'s cash runway?
Based on fiscal year 2025 data, Citius Oncology, Inc. (CTOR) had $3.9M in cash against an annual operating cash burn of $5.5M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Citius Oncology, Inc.'s Piotroski F-Score?
Citius Oncology, Inc. (CTOR) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Citius Oncology, Inc.'s earnings high quality?
Citius Oncology, Inc. (CTOR) has an earnings quality ratio of 0.22x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Citius Oncology, Inc. cover its interest payments?
Citius Oncology, Inc. (CTOR) has an interest coverage ratio of -107.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Citius Oncology, Inc.?
Citius Oncology, Inc. (CTOR) scores 14 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.